TY - JOUR
T1 - Bcl-B expression in human epithelial and nonepithelial malignancies
AU - Krajewska, Maryla
AU - Kitada, Shinichi
AU - Winter, Jane N.
AU - Variakojis, Daina
AU - Lichtenstein, Alan
AU - Zhai, Dayong
AU - Cuddy, Michael
AU - Huang, Xianshu
AU - Luciano, Frederic
AU - Baker, Cheryl H.
AU - Kim, Hoguen
AU - Shin, Eunah
AU - Kennedy, Susan
AU - Olson, Allen H.
AU - Badzio, Andrzej
AU - Jassem, Jacek
AU - Meinhold-Heerlein, Ivo
AU - Duffy, Michaelj
AU - Schimmer, Aaron D.
AU - Tsao, Ming
AU - Brown, Ewan
AU - Sawyers, Anne
AU - Andreeff, Michael
AU - Mercola, Dan
AU - Krajewski, Stan
AU - Reed, John C.
PY - 2008/5/15
Y1 - 2008/5/15
N2 - Purpose: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported. Experimental Design: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival. Results: Bcl-B protein was strongly expressed in all normal plasma cells but found in only 18% of multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non-small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001). Conclusions: Tumor-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial neoplasms with distinct clinical behaviors.
AB - Purpose: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported. Experimental Design: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival. Results: Bcl-B protein was strongly expressed in all normal plasma cells but found in only 18% of multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non-small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001). Conclusions: Tumor-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial neoplasms with distinct clinical behaviors.
UR - http://www.scopus.com/inward/record.url?scp=49249102791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49249102791&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-1955
DO - 10.1158/1078-0432.CCR-07-1955
M3 - Article
C2 - 18483366
AN - SCOPUS:49249102791
SN - 1078-0432
VL - 14
SP - 3011
EP - 3021
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -